NASDAQ: DCPH |
| Healthcare / Biotechnology / USA |
13.73 | -0.2500 | -1.79% | Vol 1.71M | 1Y Perf -61.11% |
Jun 24th, 2022 16:00 DELAYED |
BID | 12.58 | ASK | 15.00 | ||
Open | 14.16 | Previous Close | 13.98 | ||
Pre-Market | - | After-Market | 13.65 | ||
- - | -0.08 -0.58% |
Target Price | 16.60 | Analyst Rating | Moderate Buy 2.40 | |
Potential % | 20.90 | Finscreener Ranking | ★★★★ — - | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★ 47.11 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★★ — - | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 22.28 | Earnings Rating | Strong Buy | |
Market Cap | 909.15M | Earnings Date | 2nd Aug 2022 | |
Alpha | 0.00 | Standard Deviation | 0.22 | |
Beta | 1.40 |
Today's Price Range 13.3814.48 | 52W Range 6.5138.91 | 5 Year PE Ratio Range -10.40-12.10 |
Summary:
Buy
Technical Indicators: | Buy |
Moving Averages: | Strong Buy |
Performance | |||
---|---|---|---|
1 Week | 16.95% | ||
1 Month | 29.90% | ||
3 Months | 54.62% | ||
6 Months | 31.26% | ||
1 Year | -61.11% | ||
3 Years | -42.04% | ||
5 Years | - | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -46.36 | |||
ROE last 12 Months | -73.73 | |||
ROA (5Y Avg) | -30.95 | |||
ROA last 12 Months | -58.23 | |||
ROC (5Y Avg) | -75.36 | |||
ROC last 12 Months | -68.32 | |||
Return on invested Capital Q | -14.72 | |||
Return on invested Capital Y | -23.70 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 2.60 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-2.40 | ||||
2.86 | ||||
7.49 | ||||
- | ||||
-3.40 | ||||
-3.85 | ||||
2.86 | ||||
4.10 | ||||
550.99M | ||||
Forward PE | -6.42 | |||
PEG | -0.09 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
3.20 | ||||
3.70 | ||||
0.09 | ||||
0.11 | ||||
-1 794.90 | ||||
Leverage Ratio | 1.30 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
96.90 | ||||
-284.70 | ||||
-281.70 | ||||
- | ||||
- |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
100.22M | ||||
1.57 | ||||
- | ||||
- |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q01 2022 | -0.84 | -0.80 | 4.76 |
Q04 2021 | -1.49 | -1.51 | -1.34 |
Q03 2021 | -1.29 | -1.37 | -6.20 |
Q02 2021 | -1.15 | -1.21 | -5.22 |
Q01 2021 | -1.08 | -1.06 | 1.85 |
Q04 2020 | -1.16 | -1.10 | 5.17 |
Q03 2020 | -1.32 | -1.13 | 14.39 |
Q02 2020 | -1.34 | -1.20 | 10.45 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2022 QR | -0.66 | 9.59 | Positive |
9/2022 QR | -0.60 | 10.45 | Positive |
12/2022 FY | -2.62 | 10.88 | Positive |
12/2023 FY | -1.70 | 28.57 | Positive |
Next Report Date | 2nd Aug 2022 |
Estimated EPS Next Report | -0.66 |
Estimates Count | 7 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 1.71M |
Shares Outstanding | 66.22K |
Shares Float | 42.76M |
Trades Count | 13.26K |
Dollar Volume | 23.72M |
Avg. Volume | 1.38M |
Avg. Weekly Volume | 1.89M |
Avg. Monthly Volume | 1.10M |
Avg. Quarterly Volume | 1.15M |
Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH) stock closed at 13.73 per share at the end of the most recent trading day (a -1.79% change compared to the prior day closing price) with a volume of 1.71M shares and market capitalization of 909.15M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 350 people. Deciphera Pharmaceuticals Inc. CEO is Steven L. Hoerter.
The one-year performance of Deciphera Pharmaceuticals Inc. stock is -61.11%, while year-to-date (YTD) performance is 40.53%. DCPH stock has a five-year performance of %. Its 52-week range is between 6.51 and 38.91, which gives DCPH stock a 52-week price range ratio of 22.28%
Deciphera Pharmaceuticals Inc. currently has a PE ratio of -2.40, a price-to-book (PB) ratio of 2.86, a price-to-sale (PS) ratio of 7.49, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -58.23%, a ROC of -68.32% and a ROE of -73.73%. The company’s profit margin is -%, its EBITDA margin is -281.70%, and its revenue ttm is $100.22 Million , which makes it $1.57 revenue per share.
Of the last four earnings reports from Deciphera Pharmaceuticals Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.66 for the next earnings report. Deciphera Pharmaceuticals Inc.’s next earnings report date is 02nd Aug 2022.
The consensus rating of Wall Street analysts for Deciphera Pharmaceuticals Inc. is Moderate Buy (2.4), with a target price of $16.6, which is +20.90% compared to the current price. The earnings rating for Deciphera Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Deciphera Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Deciphera Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 13.18, ATR14 : 0.90, CCI20 : 200.51, Chaikin Money Flow : 0.30, MACD : 0.64, Money Flow Index : 78.56, ROC : 14.80, RSI : 64.63, STOCH (14,3) : 82.72, STOCH RSI : 0.88, UO : 67.34, Williams %R : -17.28), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Deciphera Pharmaceuticals Inc. in the last 12-months were: Daniel C. Martin (Sold 2 457 shares of value $24 465 ), Daniel Flynn (Sold 1 366 shares of value $12 362 ), Daniel L. Flynn (Sold 3 134 shares of value $31 368 ), Jama Pitman (Sold 3 590 shares of value $34 696 ), Matthew L. Sherman (Sold 5 411 shares of value $116 110 ), Thomas P. Kelly (Sold 3 136 shares of value $31 386 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Moderate Buy | Moderate Buy | Moderate Buy |
Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.
CEO: Steven L. Hoerter
Telephone: +1 781 209-6400
Address: 200 Smith Street, Waltham 02451, MA, US
Number of employees: 350
Sun, 08 May 2022 12:39 GMT Deciphera Pharmaceuticals (DCPH) Receives a Sell from JonesTrading
- TipRanks. All rights reserved.Fri, 06 May 2022 01:15 GMT Analysts Conflicted on These Healthcare Names: Zymeworks (ZYME), Deciphera Pharmaceuticals (DCPH) and Arbutus Biopharma (ABUS)
- TipRanks. All rights reserved.Thu, 28 Apr 2022 12:47 GMT Deciphera Pharmaceuticals (DCPH) Receives a Hold from JMP Securities
- TipRanks. All rights reserved.Mon, 10 Jan 2022 23:05 GMT Deciphera Pharmaceuticals (DCPH) Gets a Hold Rating from JMP Securities
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.